AI’s massive energy demand could make nuclear power essential, but China leads in rapid reactor construction while US faces regulatory hurdles—SMRs may help, but their viability remains unproven.
Trump’s FDA cuts disbanded a key generic drug policy team, threatening progress on affordable alternatives to complex medications like Ozempic and inhalers—reversing $26B in consumer savings achieved during his first term.
New U.S. legislation cuts clean energy incentives but gives nuclear power until 2029, while Trump’s orders ease nuclear regulations; fusion and geothermal face tougher hurdles amid uneven policy support.
A Yale play glorifying assassination of Puerto Rico oversight board members draws criticism for factual inaccuracies and poor timing amid real-world political violence.
Proposals to impose work requirements on Medicaid expansion enrollees would cause large coverage losses and hundreds of avoidable deaths each year in many congressional districts.
The Trump administration claims to speak for American workers, but it took away the collective bargaining rights of 1 in every 15 workers protected by a union contract.
The budget legislation would gut programs for health care, food, and energy while giving enormous tax breaks to billionaires.
House Republicans Are Giving Up on U.S. Manufacturing
Claims from congressional Republicans and the Trump administration that supporting domestic manufacturing is a priority are completely undercut by their efforts to strip incentives and kill successful programs.
The House Republican budget plan would eviscerate Medicaid and food assistance and shift resources toward the wealthiest Americans.
To improve U.S. shipbuilding capacity, policymakers should learn from a successful shipbuilding program of the past, using public investment, guaranteed demand, and cooperation with the private sector to create good jobs and bolster competitiveness.
Looking at DOGE’s IRS employee cuts through the lens of lost revenue alone will exaggerate the downsides. Shrinking the workforce compels the agency to prioritize audits more carefully
The US contributes disproportionately to drug development costs.
